IMO-001
Solid tumors
A small-molecule trispecific program designed to engage multiple targets at once in solid tumors.
- Therapeutic area
- Oncology (Immuno-oncology)
- Target
- Undisclosed (trispecific)
- Modality
- Small Molecule
- Ownership
- Fully Owned
Why this program
Beyond single-target immunotherapy
Many solid tumors evade single-target immunotherapies by relying on redundant escape mechanisms. Engaging several targets simultaneously may overcome that redundancy.
A trispecific small molecule
This program pursues a small-molecule approach designed to act on three targets at once, combining the multi-target reach usually associated with biologics with the manufacturing and delivery advantages of small molecules.
How we got here
AI-guided discovery
Omic’s AI scientists searched for chemical matter capable of coordinated multi-target engagement and prioritized candidates predicted to be active across tumor subtypes. The reasoning and the sources stay attached to each candidate.
Where it stands
The program is in lead optimization. The specific targets remain undisclosed.